Stay updated with breaking news from Human Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Biohaven reported full results from the BHV-7000 Phase 1 study examining doses up to 120 mg daily, demonstrating BHV-7000 was well-tolerated at all doses...
Smart Immune to Present Details of Pioneering Clinical Study at the American Society of Hematology (ASH) Annual Meeting 2023PARIS, France, 02 Nove...
New compound added to Basilea’s clinical pipeline; upon successful completion of preclinical profiling, start of phase 2 study planned for H1 2025Upfront...
Data from the RESKUE Phase 1/2 clinical trial continues to demonstrate safety and efficacy post-FBX-101 systemic administration in patients recently receiving hematopoietic stem cell transplantation
- Nectin Therapeutics Ltd., (Nectin) a biotechnology company has extended its Series A financing to over $25M for immuno-oncology therapies